Lupin Recalls Amlodipine Besylate Tablets Due to CGMP Deviations
Lupin Limited is recalling Amlodipine Besylate tablets because they were manufactured using active pharmaceutical ingredients that failed specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The hazard involves CGMP deviations regarding ingredient specifications, which fits the criteria for a moderate severity voluntary precautionary recall without reported illness.
Plain-English summary
Lupin Limited is recalling Amlodipine Besylate Tablets USP, 10mg, 1000-count bottles. The recall involves 11,812 bottles of the prescription medication, which is manufactured for Lupin Pharmaceuticals, Inc. in Baltimore, Maryland, and manufactured by Lupin Limited in Goa, India.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the finished products were manufactured using active pharmaceutical ingredients whose intermediates failed specifications. The affected lots include G304677, G304540, G304536, G304537, G304535, G304541, G304545, G304533, G304532, G304539, G304538, and G304534, all with an expiration date of 4/2016.
The recalled product was distributed in the United States. No recalled product was distributed to any foreign consignees by Lupin. Consumers and healthcare providers should check their inventory for these specific lot numbers and stop using the product if it matches the recalled description.
The recalled product
- Product
- AMLODIPINE BESYLATE (AMLODIPINE BESYLATE)
- Brand
- AMLODIPINE BESYLATE
- Manufacturer
- Lupin Limited
- Category
- Drug — Prescription Medication
- Affected units
- 11,812
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- Lot #: G304677
- G304540
- G304536
- G304537
- G304535
- G304541
- G304545
- G304533
- G304532
- G304539
- G304538
- G304534
- Exp. 4/2016
UPCs (1)
- 0368180233022
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 2 recalled by Lupin Limited under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · AMLODIPINE BESYLATE
- ModerateAmlodipine Besylate 10 mg Tablets Recalled for Failing Potency Tests
FDA (Drugs) · 2023-07-19
- ModerateInvaGen Recalls Amlodipine Besylate Tablets Due to Subpotency
FDA (Drugs) · 2018-10-17
- ModerateAscend Amlodipine Besylate Tablets Recalled for Foreign Tablet Presence
FDA (Drugs) · 2017-09-20
- LowLupin Recalls Amlodipine Besylate Tablets Due to CGMP Deviations
FDA (Drugs) · 2016-09-14
- LowZydus Recalls Amlodipine Besylate Tablets Due to Discoloration
FDA (Drugs) · 2014-12-03
Same manufacturer · Lupin Limited
See all →- ModerateLupin Recalls Pravastatin Sodium Tablets Due to Foreign Capsule Presence
FDA (Drugs) · 2017-11-29
- LowLupin Recalls Escitalopram Tablets Due to Incorrect or Missing Lot and Expiration Dates
FDA (Drugs) · 2016-09-28
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19